Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2008 4
2009 7
2010 8
2011 5
2012 3
2014 2
2015 4
2016 1
2017 6
2018 1
2019 2
2020 1
2021 1
2022 5
2023 3
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

48 results

Results by year

Filters applied: . Clear all
Page 1
Masitinib for mild-to-moderate Alzheimer's disease: results from a randomized, placebo-controlled, phase 3, clinical trial.
Dubois B, López-Arrieta J, Lipschitz S, Doskas T, Spiru L, Moroz S, Venger O, Vermersch P, Moussy A, Mansfield CD, Hermine O, Tsolaki M; AB09004 Study Group Investigators. Dubois B, et al. Among authors: moussy a. Alzheimers Res Ther. 2023 Feb 28;15(1):39. doi: 10.1186/s13195-023-01169-x. Alzheimers Res Ther. 2023. PMID: 36849969 Free PMC article. Clinical Trial.
Masitinib as an add-on therapy to riluzole in patients with amyotrophic lateral sclerosis: a randomized clinical trial.
Mora JS, Genge A, Chio A, Estol CJ, Chaverri D, Hernández M, Marín S, Mascias J, Rodriguez GE, Povedano M, Paipa A, Dominguez R, Gamez J, Salvado M, Lunetta C, Ballario C, Riva N, Mandrioli J, Moussy A, Kinet JP, Auclair C, Dubreuil P, Arnold V, Mansfield CD, Hermine O; AB10015 STUDY GROUP. Mora JS, et al. Among authors: moussy a. Amyotroph Lateral Scler Frontotemporal Degener. 2020 Feb;21(1-2):5-14. doi: 10.1080/21678421.2019.1632346. Epub 2019 Jul 7. Amyotroph Lateral Scler Frontotemporal Degener. 2020. PMID: 31280619 Free article. Clinical Trial.
A critical spotlight on the paradigms of FFPE-DNA sequencing.
Steiert TA, Parra G, Gut M, Arnold N, Trotta JR, Tonda R, Moussy A, Gerber Z, Abuja PM, Zatloukal K, Röcken C, Folseraas T, Grimsrud MM, Vogel A, Goeppert B, Roessler S, Hinz S, Schafmayer C, Rosenstiel P, Deleuze JF, Gut IG, Franke A, Forster M. Steiert TA, et al. Among authors: moussy a. Nucleic Acids Res. 2023 Aug 11;51(14):7143-7162. doi: 10.1093/nar/gkad519. Nucleic Acids Res. 2023. PMID: 37351572 Free PMC article. Review.
Efficacy and Safety of Masitinib in Progressive Forms of Multiple Sclerosis: A Randomized, Phase 3, Clinical Trial.
Vermersch P, Brieva-Ruiz L, Fox RJ, Paul F, Ramio-Torrenta L, Schwab M, Moussy A, Mansfield C, Hermine O, Maciejowski M; AB07002 Study Group. Vermersch P, et al. Among authors: moussy a. Neurol Neuroimmunol Neuroinflamm. 2022 Feb 21;9(3):e1148. doi: 10.1212/NXI.0000000000001148. Print 2022 May. Neurol Neuroimmunol Neuroinflamm. 2022. PMID: 35190477 Free PMC article. Clinical Trial.
Correction: Masitinib for mild-to-moderate Alzheimer's disease: results from a randomized, placebo-controlled, phase 3, clinical trial.
Dubois B, López-Arrieta J, Lipschitz S, Doskas T, Spiru L, Moroz S, Venger O, Vermersch P, Moussy A, Mansfield CD, Hermine O, Tsolaki M; AB09004 Study Group Investigators. Dubois B, et al. Among authors: moussy a. Alzheimers Res Ther. 2023 Apr 22;15(1):85. doi: 10.1186/s13195-023-01230-9. Alzheimers Res Ther. 2023. PMID: 37087449 Free PMC article. No abstract available.
Evidence for close molecular proximity between reverting and undifferentiated cells.
Zreika S, Fourneaux C, Vallin E, Modolo L, Seraphin R, Moussy A, Ventre E, Bouvier M, Ozier-Lafontaine A, Bonnaffoux A, Picard F, Gandrillon O, Gonin-Giraud S. Zreika S, et al. Among authors: moussy a. BMC Biol. 2022 Jul 6;20(1):155. doi: 10.1186/s12915-022-01363-7. BMC Biol. 2022. PMID: 35794592 Free PMC article.
Mast Cell Diseases in Practice and Research: Issues and Perspectives Raised by Patients and Their Recommendations to the Scientific Community and Beyond.
Jennings SV, Finnerty CC, Hobart JS, Martín-Martínez M, Sinclair KA, Slee VM, Agopian J, Akin C, Álvarez-Twose I, Bonadonna P, Bowman AS, Brockow K, Bumbea H, de Haro C, Fok JS, Hartmann K, Hegmann N, Hermine O, Kalisiak M, Katelaris CH, Kurz J, Marcis P, Mayne D, Mendoza D, Moussy A, Mudretzkyj G, Vaia NN, Niedoszytko M, Elberink HO, Orfao A, Radia DH, Rosenmeier S, Ribada E, Schinhofen W, Schwaab J, Siebenhaar F, Triggiani M, Tripodo G, Velazquez R, Wielink Y, Wimazal F, Yigit T, Zubrinich C, Valent P. Jennings SV, et al. Among authors: moussy a. J Allergy Clin Immunol Pract. 2022 Aug;10(8):2039-2051. doi: 10.1016/j.jaip.2022.06.018. Epub 2022 Jun 28. J Allergy Clin Immunol Pract. 2022. PMID: 35777651 Free article.
Differentiation is accompanied by a progressive loss in transcriptional memory.
Fourneaux C, Racine L, Koering C, Dussurgey S, Vallin E, Moussy A, Parmentier R, Brunard F, Stockholm D, Modolo L, Picard F, Gandrillon O, Paldi A, Gonin-Giraud S. Fourneaux C, et al. Among authors: moussy a. BMC Biol. 2024 Mar 12;22(1):58. doi: 10.1186/s12915-024-01846-9. BMC Biol. 2024. PMID: 38468285 Free PMC article.
Pharmacokinetics of masitinib in cats.
Bellamy F, Bader T, Moussy A, Hermine O. Bellamy F, et al. Among authors: moussy a. Vet Res Commun. 2009 Dec;33(8):831-7. doi: 10.1007/s11259-009-9231-6. Vet Res Commun. 2009. PMID: 19533403
48 results